Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cindy Jacobs

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The Journal of Rheumatology|March 1, 2003
Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trialArthur Kavanaugh, Mark Genovese, Jan Baughman, et al.
European Urology|November 24, 2018
Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 TrialKate L Mahon, Wenjia Qu, Hui-Ming Lin, et al.
The Oncologist|August 18, 2019
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE TrialDavid R Spigel, Dianna L Shipley, David M Waterhouse, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
British Journal of Cancer|May 17, 2018
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)Jonathan E Rosenberg, Noah M Hahn, Meredith M Regan, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Journal of Rheumatology|March 1, 2003
Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trialArthur Kavanaugh, Mark Genovese, Jan Baughman, et al.
European Urology|November 24, 2018
Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 TrialKate L Mahon, Wenjia Qu, Hui-Ming Lin, et al.
The Oncologist|August 18, 2019
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE TrialDavid R Spigel, Dianna L Shipley, David M Waterhouse, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
British Journal of Cancer|May 17, 2018
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)Jonathan E Rosenberg, Noah M Hahn, Meredith M Regan, et al.
Pageof 2